Magnetic resonance–guided focused ultrasound thalamotomy is an innovative minimally invasive treatment for medication-resistant tremor in patients with essential tremor and Parkinson disease. Sedation with common hypnotic agents is discouraged because the patient’s cooperation is required during the procedure, and these drugs interact with the patient’s tremor, interfering with the results of intraprocedural neurological evaluations. Dexmedetomidine may be the best choice for sedation during magnetic resonance–guided focused ultrasound thalamotomy, which can be prolonged and poorly tolerated by the awake patient. We report the first use of dexmedetomidine for sedation in magnetic resonance–guided focused ultrasound thalamotomy in 3 patients: none of them experienced relevant hemodynamic changes or apnea.
From the *Department of Anesthesia and Intensive Care Unit, San Salvatore Academic Hospital of L’Aquila, L’Aquila, Italy
†Department of Life, Health and Environmental Sciences, University of L’Aquila, L’Aquila, Italy
‡Department of Anesthesia, Resuscitation, Intensive and Pain Care, University of Chieti, L’Aquila, Italy
§Department of Anesthesia and Intensive Care Unit, S S Filippo e Nicola Academic Hospital of Avezzano, Avezzano, Italy
∥Department of Anesthesia and Perioperative Medicine, A.S.S.T. of Cremona, Cremona, Italy
Departments of ¶Radiology
#Biotechnological and Applied Clinical Sciences, University of L’Aquila, Aquila, Italy
**Department of Anesthesia and Intensive Care Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy.
Accepted for publication November 6, 2018.
The authors declare no conflicts of interest.
Address correspondence to Francesca De Sanctis, MD, Via D.B. Riposati num 60, Rieti (RI) 02100, Italy. Address e-mail to email@example.com.